B2B
Thioredoxin Systems AB
Swedentxnsystems.com
Thioredoxin Systems AB develops a novel antibiotic treatment, EbsArgent™, that targets bacterial thioredoxin reductase systems to combat complicated urinary tract infections caused by antibiotic-resis
aliveunknown
unknown
Stage
About
Thioredoxin Systems AB develops a novel antibiotic treatment, EbsArgent™, that targets bacterial thioredoxin reductase systems to combat complicated urinary tract infections caused by antibiotic-resistant bacteria, currently in preclinical development.
Explore Thioredoxin Systems AB's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.